Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors
PNAS Nexus · 30.04.2024 · 3 (5)
DOI: 10.1093/pnasnexus/pgae184 ↗Kurz gefasst
Fachartikel in der Zeitschrift PNAS Nexus, online erschienen am 06.05.2024. Verfasst von Elisha R Verhaar und 4 weiteren Autor:innen. Beteiligte Einrichtung: Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 93 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAID NIH HHS, NCI NIH HHS, NIH.
Abstract (Originalsprache)
The glycoproteins MICA and MICB are upregulated on the surface of cells undergoing stress, for instance due to (viral) infection or malignant transformation. MICA/B are the ligands for the activating receptor NKG2D, found on cytotoxic immune cells like NK cells, CD8+ T cells, and γδ T cells. Upon engagement of NKG2D, these cells are activated to eradicate the MICA/B-positive targets, assisted by the secretion of cytokines. Nanobodies, or VHHs, are derived from the variable regions of camelid heavy-chain only immunoglobulins. Nanobodies are characterized by their small size, ease of production, stability, and specificity of recognition. We generated nanobodies that recognize membrane-bound MICA with high affinity. Here, we use these nanobodies as building blocks for a chimeric antigen receptor (CAR) to establish VHH-based CAR NK cells. These anti-MICA nanobody-based CAR NK cells recognize and selectively kill MICA-positive tumor cells in vitro and in vivo. We track localization of the VHH-based CAR NK cells to MICA-positive lung metastases by immuno-positron emission tomography imaging.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Program in Cellular and Molecular Medicine, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
- Department of Cell and Chemical Biology, Leiden University Medical Centre, 2333 ZA Leiden, The Netherlands.
ORCID-Profile: Elisha R Verhaar, Willemijn J C van Keizerswaard, Anouk Knoflook, Thomas Balligand, Hidde L Ploegh
Förderung
- NIAID NIH HHS
- NCI NIH HHS
- NIH
- Belgian American Educational Foundation
- Wallonie-Bruxelles International
Zitieren
APA
Verhaar, E. R., van Keizerswaard, W. J. C., Knoflook, A., Balligand, T., & Ploegh, H. L. (2024). Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors. PNAS Nexus, 3(5). https://doi.org/10.1093/pnasnexus/pgae184
Vancouver
Verhaar ER, van Keizerswaard WJC, Knoflook A, Balligand T, Ploegh HL. Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors. PNAS Nexus. 2024;3(5). doi:10.1093/pnasnexus/pgae184
BibTeX
@article{Verhaar2024,
author = {Verhaar, Elisha R and van Keizerswaard, Willemijn J C and Knoflook, Anouk and Balligand, Thomas and Ploegh, Hidde L},
title = {Nanobody-based CAR NK cells for possible immunotherapy of MICA+ tumors},
journal = {PNAS Nexus},
year = {2024},
volume = {3},
number = {5},
doi = {10.1093/pnasnexus/pgae184}
}
EUVIMED